X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/23/2867314/0/en/Curium-Enrolls-First-Prostate-Cancer-Patients-in-its-Phase-3-SOLAR-Trials.html
https://www.globenewswire.com//news-release/2024/02/06/2824070/0/en/Curium-Announces-Ioflupane-I-123-Injection-Availability-for-Friday-Patient-Use.html
https://www.prnewswire.com/news-releases/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc-302040336.html
https://www.globenewswire.com//news-release/2023/11/23/2785241/0/en/Curium-Completes-Patient-Enrollment-of-Phase-3-ECLIPSE-Trial-Ahead-of-Schedule.html
https://www.globenewswire.com/news-release/2023/08/15/2725665/0/en/Curium-Announces-Achievement-of-Co-Primary-Endpoints-in-Phase-2-of-Its-Phase-1-2-SOLAR-Clinical-Trial-Imaging-Men-With-Histologically-Proven-Prostate-Cancer-Using-Copper-Cu-64-PSMA.html
https://www.globenewswire.com/news-release/2023/07/28/2712980/0/en/Curium-Receives-Marketing-Authorization-in-the-EU-for-PYLCLARI-an-Innovative-18F-PSMA-PET-Tracer-Indicated-in-Adults-With-Prostate-Cancer.html
https://www.globenewswire.com/news-release/2023/07/21/2708709/0/en/Curium-Announces-Publication-of-18F-DCFPyL-Versus-18F-Fluoromethylcholine-Results-From-European-Phase-III-Study-PYTHON-Trial.html
https://www.globenewswire.com/news-release/2023/05/26/2676889/0/en/Curium-Receives-Positive-CHMP-Opinion-of-PYLCLARI-for-Primary-Staging-of-Patients-With-High-Risk-PCa-Prior-to-Initial-Curative-Therapy-and-to-Localize-Recurrence-of-PCa-in-Patients.html
https://www.globenewswire.com/news-release/2023/05/23/2674689/0/en/Curium-Announces-Last-Patient-Enrolled-in-Their-Phase-1-2-SOLAR-Clinical-Trial-Imaging-Men-with-Histologically-Proven-Metastatic-Prostate-Cancer-Using-Copper-Cu-64-PSMA-I-T.html
https://www.globenewswire.com/news-release/2023/03/14/2626898/0/en/Curium-Confirms-No-Supply-Challenges-in-North-America-and-Europe-for-its-Eclipse-Phase-3-Clinical-Trial.html
Market Place
Share 
